Ashwagandha in brain disorders: A review of recent developments

Zahiruddin, Sultan; Basist, Parakh; Parveen, Abida; Parveen, Rabea; Khan, Washim; Gaurav, -; Ahmad, Sayeed

doi:10.1016/j.jep.2020.112876

Cited by 68 publications

(41 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…WFA has been reported to exhibit numerous activities that could be beneficial in neurodegenerative disease [8]. Consistent with other studies of WFA activities, Kumar and colleagues report that WFA treatment induced autophagy in mutant TDP43 mice.…”

supporting

confidence: 67%

Building a Case for Withaferin A as a Treatment for FTD/ALS Syndromes

Borchelt

2021

Neurotherapeutics

View full text Add to dashboard Cite

supporting

confidence: 67%

Building a Case for Withaferin A as a Treatment for FTD/ALS Syndromes

Borchelt

2021

Neurotherapeutics

View full text Add to dashboard Cite

“…WA is a liposoluble natural compound with an ability to cross the BBB. WA exerts profound neuropharmacological effects, including promotion of neurite outgrowth, mitigation of neuritic atrophy, and facilitation of synapse reconstruction (Dar et al, 2015;Zahiruddin et al, 2020). As a newly-recognized leptin sensitizer, WA prevents obesity by potentiating hypothalamic leptin signaling (Lee et al, 2016).…”

Section: Discussionmentioning

confidence: 99%

“…Withaferin A (WA) is a steroidal lactone derived from Withania somnifera, a traditional medicinal herb prescribed for a variety of ailments owing to its anti-inflammatory, anti-tumor, anti-diabetic, and neuroprotective properties (Dutta et al, 2019). WA is highly lipid-soluble and can cross the blood-brain barrier (BBB) (Zahiruddin et al, 2020). Recently, it is reported that WA enhances leptin sensitivity and prevents obesity by targeting hypothalamic neurons.…”

Section: Introductionmentioning

confidence: 99%

Withaferin A promotes white adipose browning and prevents obesity through sympathetic nerve-activated Prdm16-FATP1 axis

Guo

Liu

Wang

et al. 2021

Preprint

View full text Add to dashboard Cite

The increasing prevalence of obesity causes demands for new strategies for obesity treatment. Withaferin A (WA) shows a great potential for obesity prevention by sensitizing leptin signaling in hypothalamus. However, the mechanism underlying weight- and adiposity-reducing effects of WA remains elusive. We report that WA induced white adipose tissue (WAT) browning, elevated energy expenditure (EE), decreased respiratory exchange ratio (RER), and prevented high-fat diet (HFD)-induced obesity. Sympathetic chemical denervation dampened WAT browning and impeded reduction of adiposity in WA-treated mice. WA up-regulated the levels of Prdm16 and FATP1 (Slc27a1) in the inguinal WAT (iWAT), and this was blocked by sympathetic denervation. Prdm16 or FATP1 knockdown in iWAT abrogated WAT browning-inducing effects of WA, and restored weight gain and adiposity in WA-treated mice. Together, these findings suggest that WA induces WAT browning through the sympathetic nerve-adipose axis; and the adipocytic Prdm16-FATP1 pathway mediates the promotive effects of WA on WAT browning.

show abstract

“…They have been linked to cholesterol lowering properties, but are also present in nootropic food supplements. Withaferin A and withanolides A and B, from Withania somnifera, are examples of neuroprotective sterols [165].…”

Section: Quinone Derivativesmentioning

confidence: 99%

Potential Herb–Drug Interactions in the Management of Age-Related Cognitive Dysfunction

et al. 2021

View full text Add to dashboard Cite

Late-life mild cognitive impairment and dementia represent a significant burden on healthcare systems and a unique challenge to medicine due to the currently limited treatment options. Plant phytochemicals have been considered in alternative, or complementary, prevention and treatment strategies. Herbals are consumed as such, or as food supplements, whose consumption has recently increased. However, these products are not exempt from adverse effects and pharmacological interactions, presenting a special risk in aged, polymedicated individuals. Understanding pharmacokinetic and pharmacodynamic interactions is warranted to avoid undesirable adverse drug reactions, which may result in unwanted side-effects or therapeutic failure. The present study reviews the potential interactions between selected bioactive compounds (170) used by seniors for cognitive enhancement and representative drugs of 10 pharmacotherapeutic classes commonly prescribed to the middle-aged adults, often multimorbid and polymedicated, to anticipate and prevent risks arising from their co-administration. A literature review was conducted to identify mutual targets affected (inhibition/induction/substrate), the frequency of which was taken as a measure of potential interaction. Although a limited number of drugs were studied, from this work, interaction with other drugs affecting the same targets may be anticipated and prevented, constituting a valuable tool for healthcare professionals in clinical practice.

show abstract

Ashwagandha in brain disorders: A review of recent developments

Cited by 68 publications

References 71 publications

Building a Case for Withaferin A as a Treatment for FTD/ALS Syndromes

Building a Case for Withaferin A as a Treatment for FTD/ALS Syndromes

Withaferin A promotes white adipose browning and prevents obesity through sympathetic nerve-activated Prdm16-FATP1 axis

Potential Herb–Drug Interactions in the Management of Age-Related Cognitive Dysfunction

Contact Info

Product

Resources

About